Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Mais filtros










Intervalo de ano de publicação
3.
Mol Genet Metab ; 124(1): 57-63, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29526615

RESUMO

Ethylmalonic encephalopathy (EE) is a devastating neurodegenerative disease caused by mutations in the ETHE1 gene critical for hydrogen sulfide (H2S) detoxification. Patients present in infancy with hypotonia, developmental delay, diarrhea, orthostatic acrocyanosis and petechiae. Biochemical findings include elevated C4, C5 acylcarnitines and lactic and ethylmalonic acid (EMA) in body fluids. Current treatment modalities include metronidazole and N-acetylcysteine (NAC) to lower the production and promote detoxification of toxic H2S. Patients are typically identified after the onset of clinical symptoms and there is limited information about long term response to treatment. We report the findings of two unrelated patients with EE, identified through newborn screening, who were managed with conventional treatment (NAC, metronidazole alternated with neomycin) and in patient 2, a novel dietary treatment restricting sulfur containing amino acids. Pathogenic mutations were confirmed in the ETHE1 gene (homozygous splice site mutation in patient 1, c.505 + 1G > A; compound heterozygous mutations in patient 2, c.131_132delAG + c.566delG). Both patients were started on metronidazole and NAC by 10 weeks of age and treated for 23 months. Patient 1 did not accept the metabolic formula due to palatability and parental refusal for gastrostomy tube placement. She demonstrated improved biomarkers (EMA, lactic acid and thiosulfate) and an attenuated clinical course. Patient 2 was started on a low methionine and cysteine diet at 8 months of age utilizing SOD Anamix® Early Years, (Nutricia). Baseline EMA levels were (642 mg/g Cr; n = 2) and decreased with medical treatment by 38% to a mean of 399 (n = 4, SD = 71, p 0.0013). With dietary treatment EMA levels were further reduced by 42% to a mean of 233 (n = 8, SD = 52, p 0.0030). Lactic acid, thiosulfates and clinical outcomes were also improved. Our long-term follow-up confirms previous reports of clinical improvement with NAC and metronidazole treatment. Additionally, our studies suggest that a diet restricted in sulfur-containing amino acids results in further improvement in clinical outcomes and biochemical markers.


Assuntos
Aminoácidos/administração & dosagem , Encefalopatias Metabólicas Congênitas/dietoterapia , Encefalopatias Metabólicas Congênitas/tratamento farmacológico , Triagem Neonatal , Púrpura/dietoterapia , Púrpura/tratamento farmacológico , Acetilcisteína/uso terapêutico , Aminoácidos/química , Biomarcadores , Encefalopatias Metabólicas Congênitas/diagnóstico , Cisteína , Dieta/métodos , Feminino , Humanos , Lactente , Recém-Nascido , Ácido Láctico/análise , Masculino , Malonatos/análise , Metionina , Metronidazol/uso terapêutico , Proteínas Mitocondriais/genética , Mutação , Proteínas de Transporte Nucleocitoplasmático/genética , Púrpura/diagnóstico , Enxofre
4.
Mol Genet Metab ; 122(3): 76-84, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-28711408

RESUMO

Carnitine transporter defect (CTD; also known as systemic primary carnitine deficiency; MIM 212140) is due to mutations in the SLC22A5 gene and leads to extremely low carnitine levels in blood and tissues. Affected individuals may develop early onset cardiomyopathy, weakness, or encephalopathy, which may be serious or even fatal. The disorder can be suggested by newborn screening. However, markedly low newborn carnitine levels can also be caused by conditions unrelated to CTD, such as the low carnitine levels often associated with normal pregnancies and some metabolic disorders occurring in the mother. In order to clarify the biochemical characteristics most useful for identification of CTD in newborns, we examined California Department of Public Health newborn screening data for CTD from 2005 to 12 and performed detailed chart reviews at six metabolic centers in California. The reviews covered 14 cases of newborn CTD, 14 cases of maternal disorders (CTD, 6 cases; glutaric aciduria, type 1, 5; medium-chain acyl CoA dehydrogenase deficiency, 2; and cobalamin C deficiency, 1), and 154 false-positive cases identified by newborn screening. Our results show that newborns with CTD identified by NBS exhibit different biochemical characteristics, compared to individuals ascertained clinically. Newborns with CTD may have NBS dried blood spot free carnitine near the lower cutoff and confirmatory plasma total and free carnitine levels near the normal lower limit, particularly if obtained within two weeks after birth. These findings raise the concern that true cases of CTD may exist that could have been missed by newborn screening. CTD should be considered as a possible diagnosis in cases with suggestive clinical features, even if CTD was thought to be excluded in the newborn period. Maternal plasma total carnitine and newborn urine total carnitine values are the most important predictors of true CTD in newborns. However, biochemical testing alone does not yield a discriminant rule to distinguish true CTD from low carnitine in newborns due to other causes. Because of this biochemical variability and overlap, molecular genetic testing is imperative to confirm CTD in newborns. Additionally, functional testing of fibroblast carnitine uptake remains necessary for cases in which other confirmatory testing is inconclusive. Even with utilization of all available diagnostic testing methods, confirmation of CTD ascertained by NBS remains lengthy and challenging. Incorporation of molecular analysis as a second tier step in NBS for CTD may be beneficial and should be investigated.


Assuntos
Cardiomiopatias/sangue , Cardiomiopatias/diagnóstico , Carnitina/sangue , Carnitina/deficiência , Carnitina/metabolismo , Hiperamonemia/sangue , Hiperamonemia/diagnóstico , Doenças Musculares/sangue , Doenças Musculares/diagnóstico , Triagem Neonatal/métodos , California , Cardiomiopatias/complicações , Carnitina/análise , Carnitina/química , Carnitina/urina , Teste em Amostras de Sangue Seco , Reações Falso-Positivas , Feminino , Fibroblastos/fisiologia , Humanos , Hiperamonemia/complicações , Recém-Nascido , Limite de Detecção , Masculino , Mães , Doenças Musculares/complicações , Mutação , Análise de Sequência de DNA , Membro 5 da Família 22 de Carreadores de Soluto/deficiência , Membro 5 da Família 22 de Carreadores de Soluto/genética
5.
Mol Genet Metab ; 119(3): 223-231, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27590926

RESUMO

Long-chain fatty acid oxidation disorders (LC-FAOD) can cause cardiac hypertrophy and cardiomyopathy, often presenting in infancy, typically leading to death or heart transplant despite ongoing treatment. Previous data on triheptanoin treatment of cardiomyopathy in LC-FAOD suggested a clinical benefit on heart function during acute failure. An additional series of LC-FAOD patients with critical emergencies associated with cardiomyopathy was treated with triheptanoin under emergency treatment or compassionate use protocols. Case reports from 10 patients (8 infants) with moderate or severe cardiomyopathy associated with LC-FAOD are summarized. The majority of these patients were detected by newborn screening, with follow up confirmatory testing, including mutation analysis; all patients were managed with standard treatment, including medium chain triglyceride (MCT) oil. While on this regimen, they presented with acute heart failure requiring hospitalization and cardiac support (ventilation, ECMO, vasopressors) and, in some cases, resuscitation. The patients discontinued MCT oil and began treatment with triheptanoin, an investigational drug. Triheptanoin is expected to provide anaplerotic metabolites, to replace deficient TCA cycle intermediates and improve effective energy metabolism. Cardiac function was measured by echocardiography and ejection fraction (EF) was assessed. EF was moderately to severely impaired prior to triheptanoin treatment, ranging from 12-45%. Improvements in EF began between 2 and 21days following initiation of triheptanoin, and peaked at 33-71%, with 9 of 10 patients achieving EF in the normal range. Continued treatment was associated with longer-term stabilization of clinical signs of cardiomyopathy. The most common adverse event observed was gastrointestinal distress. Of the 10 patients, 7 have continued on treatment, 1 elected to discontinue due to tolerability issues, and 2 patients died from other causes. Two of the case histories illustrate that cardiomyopathy may also develop later in childhood and/or persist into adulthood. Overall, the presented cases suggest a therapeutic effect of triheptanoin in the management of acute cardiomyopathy associated with LC-FAOD.


Assuntos
Cardiomiopatias/tratamento farmacológico , Erros Inatos do Metabolismo Lipídico/tratamento farmacológico , Triglicerídeos/administração & dosagem , Adolescente , Cardiomiopatias/complicações , Cardiomiopatias/metabolismo , Cardiomiopatias/patologia , Criança , Pré-Escolar , Ensaios Clínicos como Assunto , Metabolismo Energético/efeitos dos fármacos , Ácidos Graxos/metabolismo , Feminino , Humanos , Lactente , Recém-Nascido , Erros Inatos do Metabolismo Lipídico/complicações , Erros Inatos do Metabolismo Lipídico/patologia , Masculino , Oxirredução/efeitos dos fármacos , Triglicerídeos/efeitos adversos
6.
Mol Genet Metab Rep ; 1: 368-372, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-27896110

RESUMO

Biotin-thiamine responsive basal ganglia disease (BTBGD) is a rare metabolic condition caused by mutations in the SLC19A3 gene. BTBGD presents with encephalopathy and significant disease progression when not treated with biotin and/or thiamine. We present a patient of Mexican and European ancestry diagnosed with BTBGD found to have compound heterozygous frameshift mutations, one novel. Our report adds to the genotype-phenotype correlation, highlighting the clinical importance of considering SLC19A3 gene defects as part of the differential diagnosis for Leigh syndrome.

7.
Mol Genet Metab ; 106(1): 104-7, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22424738

RESUMO

PURPOSE: Pearson syndrome is a very rare metabolic disorder that is usually present in infancy with transfusion dependent macrocytic anemia and multiorgan involvement including exocrine pancreas, liver and renal tubular defects. The disease is secondary to a mitochondrial DNA deletion that is variable in size and location. Endocrine abnormalities can develop, but are usually not part of the initial presentation. We report two patients who presented with unusual endocrine manifestations, neonatal diabetes and adrenal insufficiency, who were both later diagnosed with Pearson syndrome. METHODS: Medical records were reviewed. Confirmatory testing included: mitochondrial DNA deletion testing and sequencing of the breakpoints, muscle biopsy, and bone marrow studies. RESULTS: Case 1 presented with hyperglycemia requiring insulin at birth. She had several episodes of ketoacidosis triggered by stress and labile blood glucose control. Workup for genetic causes of neonatal diabetes was negative. She had transfusion dependent anemia and died at 24 months due to multisystem organ failure. Case 2 presented with adrenal insufficiency and anemia during inturcurrent illness, requiring steroid replacement since 37 months of age. He is currently 4 years old and has mild anemia. Mitochondrial DNA studies confirmed a 4.9 kb deletion in patient 1 and a 5.1 kb deletion in patient 2. CONCLUSION: The patients reported highlight the importance of considering mitochondrial DNA disorders in patients with early onset endocrine dysfunction, and expand the knowledge about this rare mitochondrial disease.


Assuntos
Insuficiência Adrenal , Anemia Sideroblástica/genética , DNA Mitocondrial/genética , Diabetes Mellitus , Sistema Endócrino , Doenças Mitocondriais/genética , Deleção de Sequência/genética , Acil-CoA Desidrogenase de Cadeia Longa/deficiência , Insuficiência Adrenal/genética , Insuficiência Adrenal/patologia , Insuficiência Adrenal/terapia , Anemia/genética , Anemia/patologia , Anemia Sideroblástica/complicações , Glicemia/genética , Glicemia/metabolismo , Síndrome Congênita de Insuficiência da Medula Óssea , Deficiências do Desenvolvimento/metabolismo , Deficiências do Desenvolvimento/patologia , Diabetes Mellitus/genética , Diabetes Mellitus/patologia , Diabetes Mellitus/terapia , Sistema Endócrino/patologia , Feminino , Terapia de Reposição Hormonal , Humanos , Hiperglicemia/metabolismo , Hiperglicemia/patologia , Recém-Nascido , Insulina/administração & dosagem , Insulina/metabolismo , Erros Inatos do Metabolismo Lipídico , Masculino , Doenças Mitocondriais/complicações , Doenças Musculares
8.
Mol Genet Metab ; 105(1): 126-31, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22115770

RESUMO

PURPOSE: To present clinical, biochemical and molecular information on six new clinically diagnosed Krabbe disease patients and assess the sensitivity of retrospective galactocerebrosidase measurement in their newborn screening samples. METHODS: Medical records were reviewed. Galactocerebrosidase activity was measured in leukocytes and, retrospectively, in the patients' newborn screening cards (stored for 1.4 to 13.5 years). GALC gene mutation analysis was performed. RESULTS: Five patients with Krabbe disease, one of whom also had hydrocephalus, became symptomatic during infancy. A sixth patient presented with seizures and developmental regression at age two and had a protracted disease course. Galactocerebrosidase activity in leukocytes ranged from 0.00 to 0.20 nmol/h/mg protein. Low galactocerebrosidase activity (range: 3.2% to 11.1% of the daily mean), consistent with Krabbe disease, was detected in each of the newborn screening samples. GALC molecular analysis identified six previously unreported mutations and two novel sequence variants. CONCLUSION: Our cases highlight the clinical variability of Krabbe disease. Galactocerebrosidase activity in newborn dried blood spots is a highly sensitive test, even when samples have been stored for many years. The high frequency of private mutations in the GALC gene may limit the use of genetic information for making treatment decisions in the newborn period.


Assuntos
Leucodistrofia de Células Globoides/diagnóstico , Leucodistrofia de Células Globoides/patologia , Triagem Neonatal , Adolescente , Encéfalo/patologia , Criança , Pré-Escolar , Análise Mutacional de DNA , Teste em Amostras de Sangue Seco , Evolução Fatal , Feminino , Galactosilceramidase/metabolismo , Humanos , Lactente , Recém-Nascido , Leucodistrofia de Células Globoides/sangue , Leucodistrofia de Células Globoides/enzimologia , Imageamento por Ressonância Magnética , Masculino , Estudos Retrospectivos
9.
Mol Genet Metab ; 103(1): 92-5, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21354840

RESUMO

Prior to the advent of expanded newborn screening, sudden and unexplained death was often the first and only symptom of medium-chain acyl-CoA dehydrogenase deficiency (MCADD). With the use of tandem mass spectrometry, infants can now be identified and treated before a life threatening metabolic decompensation occurs. Newborn screening has also been shown to detect previously undiagnosed maternal inborn errors of metabolism. We have now diagnosed two women with MCADD following the identification of low free carnitine in their newborns. While one of the women reported prior symptoms of fasting intolerance, neither had a history of metabolic decompensation or other symptoms consistent with a fatty acid oxidation disorder. These cases illustrate the importance of including urine organic acid analysis and an acylcarnitine profile as part of the confirmatory testing algorithm for mothers when low free carnitine is identified in their infants.


Assuntos
Erros Inatos do Metabolismo Lipídico , Triagem Neonatal , Acil-CoA Desidrogenase/deficiência , Acil-CoA Desidrogenase/genética , Carnitina/sangue , Carnitina/urina , Feminino , Homozigoto , Humanos , Recém-Nascido , Erros Inatos do Metabolismo Lipídico/diagnóstico , Erros Inatos do Metabolismo Lipídico/dietoterapia , Erros Inatos do Metabolismo Lipídico/genética , Mutação/genética , Fenótipo , Espectrometria de Massas em Tandem
10.
Neurology ; 75(1): 64-71, 2010 Jul 06.
Artigo em Inglês | MEDLINE | ID: mdl-20505134

RESUMO

OBJECTIVE: To describe the current treatment; clinical, biochemical, and molecular findings; and clinical follow-up of patients with aromatic l-amino acid decarboxylase (AADC) deficiency. METHOD: Clinical and biochemical data of 78 patients with AADC deficiency were tabulated in a database of pediatric neurotransmitter disorders (JAKE). A total of 46 patients have been previously reported; 32 patients are described for the first time. RESULTS: In 96% of AADC-deficient patients, symptoms (hypotonia 95%, oculogyric crises 86%, and developmental retardation 63%) became clinically evident during infancy or childhood. Laboratory diagnosis is based on typical CSF markers (low homovanillic acid, 5-hydroxyindoleacidic acid, and 3-methoxy-4-hydroxyphenolglycole, and elevated 3-O-methyl-l-dopa, l-dopa, and 5-hydroxytryptophan), absent plasma AADC activity, or elevated urinary vanillactic acid. A total of 24 mutations in the DDC gene were detected in 49 patients (8 reported for the first time: p.L38P, p.Y79C, p.A110Q, p.G123R, p.I42fs, c.876G>A, p.R412W, p.I433fs) with IVS6+ 4A>T being the most common one (allele frequency 45%). CONCLUSION: Based on clinical symptoms, CSF neurotransmitters profile is highly indicative for the diagnosis of aromatic l-amino acid decarboxylase deficiency. Treatment options are limited, in many cases not beneficial, and prognosis is uncertain. Only 15 patients with a relatively mild form clearly improved on a combined therapy with pyridoxine (B6)/pyridoxal phosphate, dopamine agonists, and monoamine oxidase B inhibitors.


Assuntos
Descarboxilases de Aminoácido-L-Aromático/líquido cefalorraquidiano , Descarboxilases de Aminoácido-L-Aromático/deficiência , Adolescente , Biomarcadores/líquido cefalorraquidiano , Criança , Pré-Escolar , Seguimentos , Humanos , Lactente , Neurotransmissores/líquido cefalorraquidiano , Neurotransmissores/deficiência , Adulto Jovem
11.
Mol Genet Metab ; 100(2): 136-42, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20307994

RESUMO

Newborn screening (NBS) by tandem mass spectrometry (MS/MS) has allowed for early detection and initiation of treatment in many patients with maple syrup urine disease (MSUD) (OMIM 248600), however, a recent report suggests that variants forms may be missed. Information on these patients is limited. We present clinical, biochemical and molecular information on patients with variant forms of MSUD not detected by the California Newborn Screening Program. Between July 2005 and July 2009, 2200,000 newborns were screened in California by MS/MS. Seventeen cases of MSUD were detected and three (two siblings) were missed. Additionally, the NBS cards of two siblings with late onset MSUD, who were born pre-expanded NBS, were retrospectively analyzed. None of the five patients met criteria to be considered presumptive positive for MSUD (leucine>200micromol/L and a ratio of leucine/alanine>or=1.5). Alloisoleucine (allo-ile) was subsequently analyzed in the NBS cards of all five patients, two of whom were found to have elevated levels. The proband in each family was diagnosed following symptoms triggered by an intercurrent illness or increased protein intake. At diagnosis, leucine levels ranged between 561 and >4528micromol/L, and allo-ile ranged from 137 to 239micromol/L. Two affected siblings had normal plasma amino acids when asymptomatic; however, their biochemical profiles were diagnostic of MSUD during intercurrent illnesses. The median age at diagnosis of all patients was one year (range 0.8-6.7). Heterozygous BCKDHB (E1beta) mutations (c.832G>A/c.970C>T) were identified in one family and a homozygous DBT (E2) sequence variant (c.1430 T>G) in another. The third family had one identifiable DBT mutation (c.827T>G), however, a second mutation was not detected. This report provides further evidence that NBS by MS/MS is unable to detect all cases of MSUD. Second-tier testing with allo-ile may improve sensitivity; however, some children with variant forms will invariably be missed.


Assuntos
Doença da Urina de Xarope de Bordo/diagnóstico , Doença da Urina de Xarope de Bordo/genética , Triagem Neonatal , Aminoácidos de Cadeia Ramificada/sangue , Criança , Pré-Escolar , Dieta com Restrição de Proteínas , Humanos , Recém-Nascido , Isoleucina/sangue , Leucina/sangue , Masculino , Triagem Neonatal/métodos , Espectrometria de Massas em Tandem
12.
Mol Genet Metab ; 96(1): 38-43, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19027335

RESUMO

Guanidinoacetate methyltransferase (GAMT) deficiency is a disorder of creatine biosynthesis, characterized by excessive amounts of guanidinoacetate in body fluids, deficiency of creatine in the brain, and presence of mutations in the GAMT gene. We present here 8 new patients with GAMT deficiency along with their clinical, biochemical and molecular data. The age at diagnosis of our patients ranges from 0 to 14 years. The age of onset of seizures usually ranges from infancy to 3 years. However, one of our patients developed seizures at age 5; progressing to myoclonic epilepsy at age 8 years and another patient has not developed seizures at age 17 years. Five novel mutations were identified: c.37ins26 (p.G13PfsX38), c.403G>T (p.D135Y), c.507_521dup15 (p.C169_S173dup), c.402C>G (p.Y134X) and c.610_611delAGinsGAA (p.R204EfsX63). Six patients had the c.327G>A (last nucleotide of exon 2) splice-site mutation which suggests that this is one of the most common mutations in the GAMT gene, second only to the known Portuguese founder mutation, c.59G>C (p.W20S). Our data suggests that the clinical presentation can be variable and the diagnosis may be overlooked due to unawareness of this disorder. Therefore, GAMT deficiency should be considered in the differential diagnosis of progressive myoclonic epilepsy as well as in unexplained developmental delay or regression with dystonia, even if the patient has no history of seizures. As more patients are reported, the prevalence of GAMT deficiency will become known and guidelines for prenatal diagnosis, newborn screening, presymptomatic testing and treatment, will need to be formulated.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/enzimologia , Guanidinoacetato N-Metiltransferase/deficiência , Guanidinoacetato N-Metiltransferase/genética , Adolescente , Erros Inatos do Metabolismo dos Aminoácidos/genética , Erros Inatos do Metabolismo dos Aminoácidos/terapia , Criança , Pré-Escolar , Creatina/deficiência , Feminino , Humanos , Lactente , Masculino , Mutação , Convulsões/enzimologia , Convulsões/genética , Convulsões/terapia
13.
Mitochondrion ; 8(2): 136-45, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18078792

RESUMO

Mutations of mitochondrial genome are responsible for respiratory chain defects in numerous patients. We have used a strategy, based on the use of a mismatch-specific DNA endonuclease named " Surveyor Nuclease", for screening the entire mtDNA in a group of 50 patients with neuromuscular features, suggesting a respiratory chain dysfunction. We identified mtDNA mutations in 20% of patients (10/50). Among the identified mutations, four are not found in any mitochondrial database and have not been reported previously. We also confirm that mtDNA polymorphisms are frequently found in a heteroplasmic state (15 different polymorphisms were identified among which five were novel).


Assuntos
DNA Mitocondrial/genética , Endonucleases , Testes Genéticos/métodos , Doenças Neuromusculares/genética , Adolescente , Adulto , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Doenças Mitocondriais/genética , Linhagem
14.
Pediatr Res ; 50(1): 61-6, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11420420

RESUMO

The treatment of multiple acyl-CoA-dehydrogenase deficiency (MADD) includes a low-fat, low-protein, high-carbohydrate diet, avoiding long fasting periods. However, there is no useful biochemical marker to determine the response to different diets or fasting periods. The aims of this study are to report a patient with MADD, diagnosed through a newborn screening program using tandem mass spectrometry, to assess her response to different feedings, and to evaluate the usefulness of acylcarnitines and FFA to monitor the response to dietary changes. The patient was diagnosed at 6 d. Family history revealed three dead siblings. Five tests were performed, one with breast milk and the subsequent four after giving the patient a bottle of a low-fat, low-protein formula (F), F with glucose polymers (GP), F+GP plus uncooked corn starch (CS), or F+GP+CS preceded by amylase. The results showed that acylcarnitines, FFA, and total nonesterified fatty acids levels were greatly improved at 2 and 4 h on F+GP compared with breast milk. At 6 mo of age, the test with F+CS was repeated to assess the response to a longer fast. The results were similar at 2 and 4 h, but showed a marked increase of acylcarnitines, FFA, and total nonesterified fatty acids at 6 h. The increase of these metabolites could not be avoided by the use of F+GP+CS, but was prevented when amylase was used simultaneously. The patient is currently 3.9 y old and has normal growth and development. We conclude that diagnosis of MADD through a newborn screening program using tandem mass spectrometry is suitable; acylcarnitines and FFA are useful to monitor the response to treatment; and exogenous amylase allows the use of CS in small children with MADD. This therapeutic approach may be an alternative to the use of continuous overnight feedings used for young children with severe fatty acid oxidation defects. Early diagnosis and treatment may change the natural history of MADD.


Assuntos
Acil-CoA Desidrogenases/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/fisiopatologia , Carnitina/análogos & derivados , Carnitina/sangue , Dieta , Ácidos Graxos/sangue , Erros Inatos do Metabolismo Lipídico/fisiopatologia , Acil-CoA Desidrogenase , Erros Inatos do Metabolismo dos Aminoácidos/sangue , Erros Inatos do Metabolismo dos Aminoácidos/dietoterapia , Feminino , Humanos , Recém-Nascido , Erros Inatos do Metabolismo Lipídico/sangue , Erros Inatos do Metabolismo Lipídico/dietoterapia , Triagem Neonatal
16.
J Inherit Metab Dis ; 21(6): 624-30, 1998 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9762597

RESUMO

Tandem mass spectrometric analysis of acylcarnitines and amino acids has been applied in newborn screening programmes for the detection of several inborn errors of metabolism. We report a false positive result for isovaleric acidaemia in a newborn screening programme using this method. The newborn screening sample showed a very prominent signal corresponding to the mass of isovalerylcarnitine. Repeat samples (age 6 days) of blood and urine showed similar results. However, urine organic acids were normal. Acylcarnitine analysis in blood, breast milk and urine of the mother also showed a prominent signal of the same mass. Gas chromatography-mass spectrometry of the methyl esters demonstrated that the signal in the patient's urine was due to the presence of pivaloylcarnitine, which is isomeric with isovalerylcarnitine. The patient's mother was receiving an antibiotic containing a derivative of pivalic acid to treat a urinary tract infection. Follow-up samples in the patient and the mother confirmed a decrease in the levels of pivaloylcarnitine, concomitant with the discontinuation of the treatment. We conclude that pivaloylcarnitine can give a false positive result for isovaleric acidaemia in newborns whose mothers are on treatment with pivoxilsulbactam-containing antibiotics.


Assuntos
Carnitina/análogos & derivados , Erros Inatos do Metabolismo/diagnóstico , Triagem Neonatal , Ácidos Pentanoicos/sangue , Carnitina/sangue , Carnitina/urina , Reações Falso-Positivas , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Hemiterpenos , Humanos , Recém-Nascido , Espectrometria de Massas , Sulbactam/análogos & derivados , Sulbactam/sangue , Sulbactam/uso terapêutico , Sulbactam/urina , Infecções Urinárias/tratamento farmacológico
17.
Metabolism ; 46(8): 851-6, 1997 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9258264

RESUMO

Hutchinson-Gilford progeria syndrome (HGPS) is a rare condition with an unknown molecular defect. Patients with HGP progressively develop failure to thrive (FTT), alopecia, loss of subcutaneous fat, scleroderma, stiffening of various joints, and severe atherosclerosis. The median life span is 13 years, and the main cause of death is cardiovascular complications. There are few reports of endocrine and metabolic studies because of the rarity of this condition, and the response to long-term growth hormone (GH) treatment has not been described. We report the results of endocrine and metabolic studies performed to investigate the etiology of growth failure in five patients with HGP. Additionally, the response to nutritional therapy (NT) and GH treatment in three of these patients is presented. Our results suggest that elevated GH levels are characteristic of this disease and that an elevated basal metabolic rate (BMR) could be the cause of the FTT seen in HGP. Nonaggressive NT slightly improved weight gain and growth velocity (GV). Combined NT and GH treatment in three patients improved the GV, increased the levels of growth factors, and paradoxically resulted in decreased BMRs. However, the response to these therapies decreased over time and did not seem to prevent the progression of atherosclerotic disease.


Assuntos
Hormônio do Crescimento/uso terapêutico , Progéria/dietoterapia , Progéria/tratamento farmacológico , Adolescente , Glicemia/metabolismo , Criança , Pré-Escolar , Feminino , Hemoglobinas Glicadas/metabolismo , Humanos , Lactente , Insulina/sangue , Masculino , Progéria/sangue
18.
Metabolism ; 46(4): 445-9, 1997 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9109852

RESUMO

Since recent studies demonstrated the occurrence of the mitochondrial DNA (mtDNA) mutation A3243G in patients with adult-onset diabetes, an investigation was undertaken to determine the frequency of this mutation in a pediatric population with insulin-dependent diabetes mellitus (IDDM). DNA was extracted from peripheral blood of 270 pediatric patients with IDDM. The presence of the mtDNA A3243G mutation was screened for by minisequencing and mutation-specific ApaI endonuclease restriction after polymerase chain reaction (PCR) amplification of mtDNA. The A3243G mtDNA mutation was not found in any IDDM patients examined. This mutation is uncommon in children with IDDM from various ethnic and racial groups. Therefore, the contribution of the mutation to the pathogenesis of IDDM, if any, is minimal.


Assuntos
DNA Mitocondrial/genética , Diabetes Mellitus Tipo 1/genética , Mutação , Adolescente , Adulto , Criança , Pré-Escolar , Humanos , Lactente , Reação em Cadeia da Polimerase , Mapeamento por Restrição
19.
Prenat Diagn ; 16(4): 333-6, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8734807

RESUMO

Glycogen storage disease type Ia (GSD Ia, von Gierke disease) is an autosomal recessive inborn error of metabolism caused by the deficiency of D-glucose-6-phosphatase (G6Pase). Since this enzyme is expressed primarily in hepatocytes, couples at risk for GSD type Ia relied on fetal liver biopsy for prenatal diagnosis. The recent isolation of the G6Pase gene and identification of several disease-causing mutations have permitted molecular prenatal diagnosis using amniocytes or chorionic villi. Chorionic villus sampling (CVS) was performed in an Ashkenazi Jewish family in whom a previous child was homoallelic and both parents were heterozygous for the R83C mutation. Molecular analysis revealed that the fetus was not affected. The prenatal diagnosis was confirmed postnatally by biochemical and molecular studies. Thus, the molecular prenatal diagnosis of GSD type Ia can be safely and accurately made in the first trimester.


Assuntos
Amostra da Vilosidade Coriônica , Doença de Depósito de Glicogênio Tipo I/diagnóstico , Sequência de Bases , Células Cultivadas , DNA/isolamento & purificação , Feminino , Glucose-6-Fosfatase/genética , Heterozigoto , Humanos , Recém-Nascido , Judeus , Masculino , Dados de Sequência Molecular , Mutação , Linhagem , Gravidez , Resultado da Gravidez , Primeiro Trimestre da Gravidez
20.
Medicina (B Aires) ; 56(3): 279-83, 1996.
Artigo em Espanhol | MEDLINE | ID: mdl-9035485

RESUMO

A 33 year old woman with episodes of severe hypoglycemia is presented. The studies showed anti-insulin antibodies and variable C-peptide levels. Circulating insulin measured after acid-ethanol extraction, was of 1,600 uU/ml and shown to be human insulin after characterization by HLPC. Specific anti-human insulin antibodies were of high affinity (Ka1: 6.20 x 10(10) M-1; Ka2: 2.42 x 10(9) M-1). A small cross-reactive porcine and bovine antibody subpopulation was also detected (IgG, light k type chain). Plasmapheresis was undertaken when symptoms were spontaneously declining and turned antibody title negative. Prolonged follow-up showed no relapse of this syndrome.


Assuntos
Doenças Autoimunes/imunologia , Hipoglicemia/imunologia , Anticorpos Anti-Insulina , Adulto , Doenças Autoimunes/terapia , Cromatografia de Afinidade , Reações Cruzadas , Feminino , Humanos , Hipoglicemia/terapia , Insulina/sangue , Plasmaferese , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...